{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03974204",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Exo-LCR-1807"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2018-A02358-47",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "NÂ°ID RCB"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Centre Oscar Lambret",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.",
      "OfficialTitle": "Benefit of Analyzing Exosomes in the Cerebrospinal Fluid During the Medical Care of Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis."
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2021",
      "OverallStatus": "Withdrawn",
      "WhyStopped": "Modification of the care habits. We believe today that we are no longer able to carry out this study as initially described.",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2019",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "May 31, 2019",
      "StudyFirstSubmitQCDate": "June 3, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 4, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 5, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 12, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Centre Oscar Lambret",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a multicenter, interventional, prospective study among breast cancer patients with a suspicion of metastatic meningitis. The current study aims to assess the use of proteomic profile issued from cerebrospinal fluid microvesicles for diagnosis of leptomeningeal metastases.",
      "DetailedDescription": "The aim of this study is to describe the association between the initial proteomic profile issued from cerebrospinal fluid microvesicles and the initial cytological analysis of the cerebrospinal fluid in breast cancer patients with a suspicion of metastatic meningitis.\n\nOther objectives of the study include:\n\nDescribing the association between the initial proteomic profile and:\n\nthe histological types and hormonal receptors status of the breast cancer,\nthe likelihood of leptomeningeal metastasis according to the EANO-ESMO classification (Lack of evidence / possible / probable / confirmed) ,\nthe likelihood of leptomeningeal metastasis according to the EANO-ESMO classification, combined with histological type and hormonal receptors status.\nEvaluate the prognostic value of the proteomic profiling for overall survival, according to the EANO-ESMO classification and other known prognosis factors, in patients classified \"possible\", \"probable\" or \"confirmed\" leading to leptomeningeal metastases specific treatment,\nEvaluate the impact of the evolution of the proteomic profile a month after the start of this treatment on the overall survival, in patients with leptomeningeal metastases specific treatment,\nEvaluate the association between the proteomic profile and the EANO-ESMO classification at least 3 months after the initial EANO-ESMO classification,\nEvaluate the evolution of the proteomic profile 3 months after the initial EANO-ESMO classification, in patients initially classified \"lack of evidence\", broadly and according to the evolution of cytology, the administered treatments and to the EANO-ESMO response if applicable,\nCompare the proteomic profiles issued from cerebrospinal fluid and blood"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Breast Cancer",
          "Leptomeningeal Metastasis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Cerebrospinal fluid",
          "Proteomic profile"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Diagnostic",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "0",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Cerebrospinal fluid and Blood sample collection",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Collection of cerebrospinal fluid and blood samples:\n\nAt initial diagnostic assessment;\n1 month and 3 months after initial diagnostic assessment, for patients classified \"possible\", \"probable\" or \"confirmed\" according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;\nIn case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified \"lack of evidence\" according to EANO-ESMO classification.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment",
                "Procedure: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are \"Lack of evidence\" according to EANO-ESMO classification",
                "Procedure: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are \"confirmed\", \"probable\" or \"possible\", leading to leptomeningeal metastase specific treatment"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Procedure",
            "InterventionName": "Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment",
            "InterventionDescription": "At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cerebrospinal fluid and Blood sample collection"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are \"Lack of evidence\" according to EANO-ESMO classification",
            "InterventionDescription": "3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:\n\nWhen suspected metastatic meningitis symptoms arise and\nat least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cerebrospinal fluid and Blood sample collection"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are \"confirmed\", \"probable\" or \"possible\", leading to leptomeningeal metastase specific treatment",
            "InterventionDescription": "3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:\n\n1 month after the beginning of the specific treatment,\n3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cerebrospinal fluid and Blood sample collection"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Proteomic profiles issued from cerebrospinal fluid at diagnosis",
            "PrimaryOutcomeDescription": "Proteomic profile will be obtained by bioinformatic analysis of cerebrospinal fluid.",
            "PrimaryOutcomeTimeFrame": "Up to 1 week"
          },
          {
            "PrimaryOutcomeMeasure": "Cytology of cerebrospinal fluid at diagnosis",
            "PrimaryOutcomeDescription": "Results of cytological analysis of cerebrospinal fluid will be \"Positive\", \"negative\", \"equivocal\".",
            "PrimaryOutcomeTimeFrame": "Up to 1 week"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Proteomic profiles issued from cerebrospinal fluid",
            "SecondaryOutcomeDescription": "Proteomic profile will be obtained by bioinformatic analysis of cerebrospinal fluid:\n\n1 month and 3 month after the start of a specific treatment of the leptomeningeal metastasis, if applicable,\n3 months after the initial diagnosis of leptomeningeal metastasis if the likehood of leptomeningeal metastasis is \"lack of evidence\".",
            "SecondaryOutcomeTimeFrame": "Up to 3 months"
          },
          {
            "SecondaryOutcomeMeasure": "Histological subtype",
            "SecondaryOutcomeDescription": "Histological subtype will be subdivised as invasive ductal breast carcinoma, invasive lobular breast carcinoma, other brest carcinoma.",
            "SecondaryOutcomeTimeFrame": "Before registration in study"
          },
          {
            "SecondaryOutcomeMeasure": "Hormonal receptors status",
            "SecondaryOutcomeDescription": "Hormonal receptors status will be subdivised as:\n\nPositive hormonal receptors / Positive HER2\nPositive hormonal receptors / Negative HER2\nNegative hormonal receptors / Positive HER2\nTriple negative",
            "SecondaryOutcomeTimeFrame": "Before registration in study"
          },
          {
            "SecondaryOutcomeMeasure": "Likehood of leptomeningeal metastasis according to the EANO-ESMO classification.",
            "SecondaryOutcomeDescription": "EANO-ESMO classification is obtained by searching clinical symptoms, cancer cells in the cerebrospinal fluid (obtained by lumbar puncture), signs in RMI. The likehood of leptomeningeal metastasis is:\n\nLack of evidence,\nPossible,\nProbable,\nConfirmed.",
            "SecondaryOutcomeTimeFrame": "Up to 3 months after the intial diagnosis"
          },
          {
            "SecondaryOutcomeMeasure": "Overall survival",
            "SecondaryOutcomeDescription": "Overall survival is defined as time from date of registration to date of death regardless of the cause.",
            "SecondaryOutcomeTimeFrame": "Time from date of registration to date of death regardless of the cause, assessed up to 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Proteomic profiles issued from blood",
            "SecondaryOutcomeDescription": "Proteomic profile will be obtained by bioinformatic analysis of blood.",
            "SecondaryOutcomeTimeFrame": "Up to 3 months after the intial diagnosis"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatient with histologically proven breast cancer\nPatient with suspected metastatic leptomeningitis\nAge â¥ 18 years\nPatient covered by the French social security regime\nSigned written informed consent\n\nExclusion Criteria:\n\nHistory of cancer other than the one being treated\nContraindication to carrying out the lumbar puncture or cerebrospinal MRI\nPregnant or breastfeeding patient",
      "HealthyVolunteers": "No",
      "Gender": "Female",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Emilie LE RHUN, MD",
            "OverallOfficialAffiliation": "Centre Oscar Lambret",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Centre Oscar Lambret",
            "LocationCity": "Lille",
            "LocationState": "Hauts-de- France",
            "LocationZip": "59020",
            "LocationCountry": "France"
          },
          {
            "LocationFacility": "Centre Hospitalier RÃ©gional Universitaire de Lille",
            "LocationCity": "Lille",
            "LocationState": "Hauts-de-France",
            "LocationZip": "59000",
            "LocationCountry": "France"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001943",
            "ConditionMeshTerm": "Breast Neoplasms"
          },
          {
            "ConditionMeshId": "D000009362",
            "ConditionMeshTerm": "Neoplasm Metastasis"
          },
          {
            "ConditionMeshId": "D000055756",
            "ConditionMeshTerm": "Meningeal Carcinomatosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000001941",
            "ConditionAncestorTerm": "Breast Diseases"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          },
          {
            "ConditionAncestorId": "D000009385",
            "ConditionAncestorTerm": "Neoplastic Processes"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008577",
            "ConditionAncestorTerm": "Meningeal Neoplasms"
          },
          {
            "ConditionAncestorId": "D000016543",
            "ConditionAncestorTerm": "Central Nervous System Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009423",
            "ConditionAncestorTerm": "Nervous System Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M4372",
            "ConditionBrowseLeafName": "Breast Neoplasms",
            "ConditionBrowseLeafAsFound": "Breast Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11459",
            "ConditionBrowseLeafName": "Neoplasm Metastasis",
            "ConditionBrowseLeafAsFound": "Metastases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M27478",
            "ConditionBrowseLeafName": "Meningeal Carcinomatosis",
            "ConditionBrowseLeafAsFound": "Leptomeningeal Metastases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4370",
            "ConditionBrowseLeafName": "Breast Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11482",
            "ConditionBrowseLeafName": "Neoplastic Processes",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10712",
            "ConditionBrowseLeafName": "Meningeal Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11519",
            "ConditionBrowseLeafName": "Nervous System Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18089",
            "ConditionBrowseLeafName": "Central Nervous System Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          }
        ]
      }
    }
  }
}